Navidea Biopharmaceuticals Reports Second Quarter and Year-to-Date 2020 Financial Results Aug 13, 2020
Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership Aug 10, 2020
Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma Aug 10, 2020
Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update Aug 6, 2020
Navidea Biopharmaceuticals Announces Full Enrollment in its Ongoing Phase 2B Trial of Tc99m Tilmanocept in Rheumatoid Arthritis (RA) Jun 15, 2020
Navidea Biopharmaceuticals Announces Acceptance of Abstract for Presentation at the European League Against Rheumatism (EULAR) Congress Jun 3, 2020
Navidea Biopharmaceuticals Announces Positive Results of Second Interim Analysis of Ongoing Phase 2B Study in Rheumatoid Arthritis May 21, 2020
Navidea Biopharmaceuticals Regains Commercialization and Distributions Rights in Europe for LYMPHOSEEK® May 11, 2020
